Title | Author(s) | Issue date | ???itemlist.??? |
Apolipoproteins C-Ii and C-Iii and Small Dense Ldl Cholesterol Levels in Non-Diabetic Obese Subjects with Metabolic Syndrome | Filippatos, T.; Tsimihodimos, V.; Kostapanos, M.; Kostara, C.; Tzallas, C.; Bairaktari, E.; Tselepis, A.; Elisaf, M. | 24-Nov-2015 | - |
Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria | Gazi, I.; Tsimihodimos, V.; Filippatos, T.; Bairaktari, E.; Tselepis, A. D.; Elisaf, M. | 24-Nov-2015 | - |
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia | Kalogirou, M.; Tsimihodimos, V.; Gazi, I.; Filippatos, T.; Saougos, V.; Tselepis, A. D.; Mikhailidis, D. P.; Elisaf, M. | 24-Nov-2015 | - |
The effect of hypolipidaemic agents on lipoprotein-associated phospholipase A2 (Lp-PLA2) | Saougos, V.; Filippatos, T.; Kostapanos, M.; Kalogirou, M.; Tselepis, A. D.; Elisaf, M. | 24-Nov-2015 | - |
Effect of rosuvastatin on apolipoprotein CII and CIII serum levels in patients with primary dyslipidemia | Kostapanos, M.; Filippatos, T.; Milionis, H.; Kostara, C.; Bairaktari, E.; Elisaf, M. S. | 24-Nov-2015 | - |
Effect of rosuvastatin on low density lipoprotein (LDL) concentration and relative distribution in patients with primary dyslipidaemia | Kostapanos, M.; Filippatos, T.; Gazi, I.; Milionis, H.; Tselepis, A.; Elisaf, M. S. | 24-Nov-2015 | - |
Effect of rosuvastatin on low density lipoprotein (LDL) profile in patients with primary dyslipidaemia | Kostapanos, M.; Filippatos, T.; Gazi, I.; Saougos, V. G.; Milionis, H. J.; Tselepis, A. D.; Elisaf, M. S. | 24-Nov-2015 | - |
The Effects of Ezetimibe and Orlistat, Alone or in Combination, on High Density Lipoprotein (Hdl) Subclasses and Hdl-Associated Enzyme Activities in Overweight and Obese Patients with Hyperlipidaemia | Nakou, E.; Filippatos, T.; Kiortsis, D.; Derdemezis, C.; Georgoula, M.; Petraki, M.; Tselepis, A.; Elisaf, M. | 24-Nov-2015 | - |
The Effects of Ezetimibe, Alone or Combined with Orlistat, on Triglyceride-Rich Lipoprotein Metabolism in Overweight and Obese Patients with Hyperlipidaemia | Nakou, E.; Filippatos, T.; Kostara, C.; Agouridis, A.; Bairaktari, E.; Elisaf, M. S. | 24-Nov-2015 | - |
Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study | Derdemezis, C.; Filippatos, T.; Tselepis, A.; Mikhailidis, D.; Elisaf, M. S. | 24-Nov-2015 | - |
Effects of rosuvastatin on serum homocysteine, vitamin B12 and folic acid levels in patients with primary hyperlipidemia | Chasiotis, G.; Milionis, H.; Gazi, I.; Filippatos, T.; Bairaktari, E.; Elisaf, M. S.; Seferiadis, K. | 24-Nov-2015 | - |
High-Density Lipoprotein Subclasses in Patients with or without the Metabolic Syndrome | Lagos, K. G.; Gazi, I. F.; Kostapanos, M. S.; Filippatos, T.; Kazakou, P. S.; Rizos, C. V.; Tselepis, A. D.; Elisaf, M. | 24-Nov-2015 | - |
LDL subfractions in patients with metabolic syndrome | Gazi, I.; Filippatos, T.; Bairaktari, E.; Kostara, C.; Tselepis, A.; Elisaf, M. S. | 24-Nov-2015 | - |
Lipoprotein-associated phospholipase A(2) activity is a marker of small, dense LDL particles in human plasma | Gazi, I.; Lourida, E. S.; Filippatos, T.; Tsimihodimos, V.; Elisaf, M.; Tselepis, A. D. | 24-Nov-2015 | - |
Lipoprotein-associated phospholipase A2 activity (LP-PLA2) is a marker of small-dense LDL particles | Gazi, I.; Lourida, E.; Filippatos, T.; Tsimihodimos, V.; Saougos, V.; Elisaf, M.; Tselepis, A. | 24-Nov-2015 | - |
Plasma triglyceride levels and body mass index values are the most important determinants of pre beta-1 HDL concentrations in patients with various types of primary dyslipidemia | Tsimihodimos, V.; Gazi, I.; Filippatos, T.; Kostapanos, M.; Lagos, K.; Kostara, C.; Tellis, C. C.; Elisaf, M.; Tselepis, A. D. | 24-Nov-2015 | - |
Plasma Visfatin Concentration Is a Marker of an Atherogenic Metabolic Profile | Filippatos, T.; Tsimihodimos, V.; Derdemezis, C. S.; Gazi, I. F.; Saougos, V.; Tselepis, A. D.; Elisaf, M. S. | 24-Nov-2015 | - |
Rosuvastatin administration decreases apolipoprotein CII and CIII serum levels in patients with primary dysilipidaemia | Kostapanos, M.; Filippatos, T.; Gazi, I.; Saougos, V. G.; Milionis, H. J.; Kostara, C.; Bairaktari, E.; Elisaf, M. S. | 24-Nov-2015 | - |
Treatment of hyperlipidaemia with fenofibrate and related fibrates | Filippatos, T.; Milionis, H. J. | 24-Nov-2015 | - |